Skip to main content

Enspryng Prices, Coupons, Copay Cards & Patient Assistance

Enspryng (satralizumab) is a member of the interleukin inhibitors drug class and is commonly used for Neuromyelitis Optica Spectrum Disorder.

The cost for Enspryng (120 mg/mL) subcutaneous solution is around $18,096 for a supply of 1 milliliter(s), depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.

Enspryng prices

Subcutaneous Solution

120 mg/mL

Enspryng subcutaneous solution

 from $18,096.04

for 1 milliliter(s)
Quantity Per unit Price
1 milliliter $18,096.04 $18,096.04

Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.

Enspryng Coupons, Copay Cards and Rebates

Enspryng offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.

Drugs.com Printable Discount Card

The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.

Print Free Discount Card

Note: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, CVS Pharmacy, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.

Enspryng Co-pay Program

Eligible commercially insured patients may pay$0 per prescription; maximum savings of $20,000 per calendar year.

Applies to:
Enspryng
Number of uses:
Per prescription per calendar year

Form more information phone: 800-636-0373 or Visit website

Enspryng Co-pay Program Reimbursement Request Form

Eligible commercially insured patients may apply for reimbursement after paying in full for their prescription.

Applies to:
Enspryng
Number of uses:
One rebate per prescription fill

Form more information phone: 800-636-0373 or Visit website

Patient Assistance & Copay Programs for Enspryng

Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.

Provider: Patient Access Network Foundation (PAN)

Eligibility requirements:
  1. *See Additional Information section below
  2. Between 400-500% of FPL
  3. FDA Approved Diagnosis - See Program Website for Details
  4. Must reside and receive treatment in US
  5. *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
Applicable drugs:
  • Enspryng (satralizumab-mwge) Injection; Subcutaneous

More information please phone: 866-316-7263 Visit Website

Provider: Good Days Program

Eligibility requirements:
  1. Must have insurance
  2. At or below 500% of FPL
  3. FDA-approved diagnosis
  4. The patient must also be a US resident with a Social Security Number.
  5. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly.
Applicable drugs:
  • Enspryng (satralizumab-mwge) Injection; Subcutaneous

More information please phone: 877-968-7233 Visit Website

Provider: Genentech Patient Foundation

Eligibility requirements:
  1. Uninsured or Underinsured with no prescription coverage for needed medication
  2. Based on FPL
  3. Medically appropriate condition/diagnosis
  4. Must be treated by US licensed healthcare provider
  5. The Genentech Access to Care Foundation is now the Genentech Patient Foundation. Eligibility determined on a case-by-case basis. Call for most recent medications as the list is subject to change. This program may provide a Bridge Program for eligible patients who experience a delay, temporary loss, or change in coverage. Contact program for details.
Applicable drugs:
  • Enspryng (satralizumab-mwge) Injection; Subcutaneous

More information please phone: 888-941-3331   or 866-422-2377   Visit Website

Provider: Genentech Access Solutions: Enspryng

Eligibility requirements:
  1. Determined case by case
  2. Based on FPL
  3. FDA-approved diagnosis
  4. Must be residing in the US or US territory
  5. Eligibility determined on a case-by-case basis. Contact program for details. Co-payment assistance, and patient assistance programs are available for eligible patients.
Applicable drugs:
  • Enspryng (satralizumab-mwge) Injection; Subcutaneous

More information please phone: 844-677-7964   or 866-422-2377   Visit Website

Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.